Eric Bauvin
Research Subjects
Research Interests
Eric Bauvin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Pascale Grosclaude
Tarn Cancer Registry, Albi, France
3 shared publications - Arnauld Villers
Department of Urology, Lille University Hospital, 59000 Lille, France
2 shared publications A Buémi
1 shared publicationAntoine Elias
1 shared publicationBenoît Dervaux
1 shared publicationCépidc
1 shared publication
Latest Publications
- 1 December 2003
- Vol. 13 (6) , 1334-9
[Incidence and mortality of prostate cancer in France: trends between 1978 and 2000].
To describe the prostate cancer incidence and mortality trends in France over the last 20 years. Incidence data were obtained from 9 cancer registries, systematically recording urological tumours. Mortality data were provided by the INSERM joint department analysing death certificates (CépiDc). There were 40,309 new cases of prostate cancer and 10,004 deaths in France in 2000. The net risk of developing prostate cancer before the age of 75 years for a patient born in 1943 was multiplied by 3 compared to those born in 1928, while the risk of death from prostate cancer slightly decreased. The standardized incidence rate was threefold higher in 2000 than in 1980, while the mortality rate has remained stable or has decreased since 1990. Comparisons between French departments and between European countries are presented. Although the incidence of prostate cancer is continuing to increase in France, the associated mortality is slightly decreasing. However, population studies are insufficient to attribute this decreased mortality to detection alone.
- 1 December 2003
- Vol. 13 (6) , 1334-9
[Incidence and mortality of prostate cancer in France: trends between 1978 and 2000].
To describe the prostate cancer incidence and mortality trends in France over the last 20 years. Incidence data were obtained from 9 cancer registries, systematically recording urological tumours. Mortality data were provided by the INSERM joint department analysing death certificates (CépiDc). There were 40,309 new cases of prostate cancer and 10,004 deaths in France in 2000. The net risk of developing prostate cancer before the age of 75 years for a patient born in 1943 was multiplied by 3 compared to those born in 1928, while the risk of death from prostate cancer slightly decreased. The standardized incidence rate was threefold higher in 2000 than in 1980, while the mortality rate has remained stable or has decreased since 1990. Comparisons between French departments and between European countries are presented. Although the incidence of prostate cancer is continuing to increase in France, the associated mortality is slightly decreasing. However, population studies are insufficient to attribute this decreased mortality to detection alone.
- 1 November 2003
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (16) , 2364-2371
Medical and non-medical determinants of prostate cancer management
- 1 November 2003
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (16) , 2364-2371
Medical and non-medical determinants of prostate cancer management
- 1 September 2003
- Vol. 13 (4) , 618-23
[Cost and efficacy of treatment strategies in localized prostatic cancer: feasibility study in the general population].
Medico-economic studies are necessary to evaluate healthcare practices. The objective of this preliminary study is to show how this type of study can be conducted in the general population based on cancer registries. 122 cases of localized prostate cancer diagnosed in 1995 in the Tarn department were included in this study. A decisional tree of the main diagnostic strategies was elaborated. Direct medical and non-medical costs were considered from the payer's point of view and the 5-year survival was calculated. The costs of therapeutic management for radical prostatectomy, localized radiotherapy, endocrine therapy and watchful waiting were 55,468, 65,486, 72,211, and 13,929 French francs (8,533, 10,075, 11,109 and 2,143 euros) respectively. The observed 5-year survival was 89%, 84%, 75% and 79% respectively. This method can be applied to the CCAFU/FRANCIM cohort derived from 5 departments allowing comparisons between regions and healthcare sectors. The time-course could be determined by follow-up of a cohort of cancers diagnosed in 2001.
- 1 September 2003
- Vol. 13 (4) , 618-23
[Cost and efficacy of treatment strategies in localized prostatic cancer: feasibility study in the general population].
Medico-economic studies are necessary to evaluate healthcare practices. The objective of this preliminary study is to show how this type of study can be conducted in the general population based on cancer registries. 122 cases of localized prostate cancer diagnosed in 1995 in the Tarn department were included in this study. A decisional tree of the main diagnostic strategies was elaborated. Direct medical and non-medical costs were considered from the payer's point of view and the 5-year survival was calculated. The costs of therapeutic management for radical prostatectomy, localized radiotherapy, endocrine therapy and watchful waiting were 55,468, 65,486, 72,211, and 13,929 French francs (8,533, 10,075, 11,109 and 2,143 euros) respectively. The observed 5-year survival was 89%, 84%, 75% and 79% respectively. This method can be applied to the CCAFU/FRANCIM cohort derived from 5 departments allowing comparisons between regions and healthcare sectors. The time-course could be determined by follow-up of a cohort of cancers diagnosed in 2001.